Article Text

Download PDFPDF

930 Comparison of clinicopathological characteristics and survival outcomes of patients with grade III endometrioid adenocarcinoma and carcinosarcoma
  1. K Güngördük1,
  2. H Plett2,
  3. V Gülseren3,
  4. MM Meydanli4,
  5. G Boyraz5,
  6. IA Ozdemir6,
  7. H Şahin7,
  8. T Şenol8,
  9. N Yildirim9,
  10. T Turan5,
  11. T Oge10,
  12. M Gokcu11,
  13. S Taşkın12,
  14. A Ayhan7 and
  15. B Ataseven2
  1. 1Mugla Sıtkı Kocman University, Muğla, Turkey
  2. 2Charité University Hospital, Berlin, Germany
  3. 3Tepecik Edication and Research Hospital, Turkey
  4. 4Zekai Tahir Burak Women’s Health Training and Research Hospital, Ankara, Turkey
  5. 5Etlik Zubeyde Hanim Women’s Health Training and Research Hospital, Turkey
  6. 6Dr Sadi Konuk Training and Research Hospital, Turkey
  7. 7Baskent University, Turkey
  8. 8Zenyep Kamil Women’s Health Education and Research Hospital, Turkey
  9. 9Ege University, Turkey
  10. 10Eskişehir Osman Gazi University, Turkey
  11. 11İzmir University of Economics Medicine Faculty Medical Park Hospital, Gynecological Oncology, İzmir, Turkey
  12. 12Ankara University, Turkey


Introduction/Background*The clinicopathologic characteristics, recurrence patterns, and survival of patients with grade III endometrial cancer (G3EC) and uterine carcinosarcoma (UCS) were compared.

Methodology The medical records of patients treated for G3EC and UCS between January 1996 and December 2016 at X gynecologic oncology centers in Turkey and Germany were analyzed.

Result(s)*UCS was diagnosed in 353 (48.2%) of the enrolled patients and G3EC in 380 (51.8%). The patients in each group were divided into three subgroups depending on the disease stage: early (stage IA), locally advanced (IB-II) and advanced (III-IV). For all stages, the recurrence rate was higher in patients with UCS than in those with G3EC. Adjuvant treatment type had no significant effect on disease-free survival (DFS) or overall survival (OS) in patients with early stage tumors. In patients with locally advanced disease, radiotherapy (RT) + chemotherapy (CT) was the most effective type of adjuvant therapy with respect to DFS and OS. In those with advanced disease, RT + CT was the most effective type of adjuvant therapy but only with respect to DFS.

Conclusion*The recurrence rate was higher in UCS patients than in G3EC patients, regardless of disease stage. DFS was of shorter duration in UCS than in G3EC patients. OS did not significantly differ between UCS and G3EC patients with early or locally advanced disease. In patients with early stage UCS or G3EC, adjuvant therapy modalities had no effect on survival. However, in both groups of patients with locally advanced disease, adjuvant CT and RT resulted in a significant improvement in DFS and OS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.